Yukako Mokutani, Junichi Nishimura, Mamoru Uemura, Naotsugu Haraguchi, Tarou Hayashi, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Masanori KishibuchI, Hirofumi Yamamoto, Yuichiro Doki and Masaki Mori
Pseudomyxoma Peritonei (PMP) is a rare disease characterized by disseminated intra-peritoneal implants and mucinous ascites.There is currently no standard treatment strategy for PMP. Presentation of case: We present an unusual case of advanced PMP concomitant with early gastric cancer in a 61-year-old male. In the first operation, in December 2007, the gastric cancer was unrespectable by extensive dissemination of PMP. Therefore, cytoreductive surgery for PMP and appendectomy were performed. After systemic chemotherapy with paclitaxel (Taxo, PTX) plus S-1 for almost 1year, the dissemination on the stomach and intestines disappeared, and we were able to perform a subtotal gastrectomy to remove early gastric cancer. Afterwards, with the intermittent administration of irinotecan (CPT-11) in addition to the basal use of S-1, the patient survived more than five years. To the present day, systemic therapy is still being administered, and might lead to stabilization of disease.
